Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced Non-small Cell Lung Cancer

Erik D’Hondt^*

Head of Research and Development and Regulatory, Bioven, UK

^*Corresponding Author: Erik D’Hondt, Head of Research and Development and Regulatory, EU HQ, Bioven Group 33 St James Square London, UK, Tel: +32473355669, Fax: +3232965548 Email:

Short-Communication